Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Centanafadine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Otsuka Pharma Seeks FDA Approval For Centanafadine In ADHD
    Otsuka Pharma Seeks FDA Approval For Centanafadine In ADHD

    24 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251124043308/en/Otsuka-Pharmaceutical-Submits-New-Drug-Application-to-U.S.-FDA-for-Centanafadine-for-the-Treatment-of-ADHD-in-Children-Adolescents-and-Adults

    BUSINESSWIRE
    24 Nov 2025
    Share Share
    Otsuka reports positive results from two phase 3 trials of centanafadine
    Otsuka reports positive results from two phase 3 trials of centanafadine

    30 Oct 2023

    // PHARMABIZ

    http://pharmabiz.com/NewsDetails.aspx?aid=163285&sid=2

    PHARMABIZ
    30 Oct 2023
    Share Share
    Otsuka Announces Positive Results From Phase 3 Trials of Centanafadine
    Otsuka Announces Positive Results From Phase 3 Trials of Centanafadine

    27 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231027187786/en

    BUSINESSWIRE
    27 Oct 2023
    Share Share